IK-930 is under clinical development by Ikena Oncology and currently in Phase I for Malignant Mesothelioma. According to GlobalData, Phase I drugs for Malignant Mesothelioma have a 77% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how IK-930’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
IK-930 is under development for the treatment of Nf2 and LATS-mutated cancers such as NF2-mutant mesothelioma, epithelioid hemangioendothelioma (EHE), a rare form of soft tissue sarcoma, non-small cell lung cancer (NSCLC) and advanced solid tumors including meningioma, cholangiocarcinoma, thymoma, NSCLC, HCC, colorectal cancer (CRC). The drug candidate is administered as tablet through oral route. It acts by targeting TEAD.
Ikena Oncology overview
Ikena Oncology, formerly Kyn Therapeutics is a health care provider. The company is advancing novel immunometabolic therapies for the treatment of cancers. Its pipeline development programs include EP4 antagonist IK-007, which promotes immune suppression across a diverse range of immune cells; AHR antagonist, prevent AHR-modulated tumor promotion; and IK-412, a kynurenine-degrading enzyme (Kynase) that targets implicated in immunosuppression across a range of tumor types through multiple immune cell effects. Its immunosuppressive pathway inhibits the IDO and TDO pathway, enabling the body’s immune system to attack the tumor. Ikena Oncology is headquartered in Boston, Massachusetts, the US.
For a complete picture of IK-930’s drug-specific PTSR and LoA scores, buy the report here.